Senators press HHS over prediction markets tied to drug trials and FDA approvals
The fight is no longer just about a fast-growing trading niche, but about whether markets on medical outcomes can be policed before they distort research and public trust.
Published July 8, 2026 · Updated November 12, 2026
Why it's worth posting
This is worth posting because the story has moved from abstract debate to direct political scrutiny. Senators Angela Alsobrooks and Ron Wyden have asked HHS what it has done to mitigate risks from prediction markets tied to clinical trials and FDA approvals, while warning that these bets could undermine the scientific process, create perverse incentives for researchers, harm trial participants, and lead to dangerous medical outcomes. That makes this a clear regulatory and ethics moment, not just another growth story about prediction markets.
A creator has a strong reason to cover this now because a new institution has entered the fight. The senators’ letter asks HHS for measures it has taken on these markets and for communications about staff participation and contacts with platforms and the CFTC. That shifts the conversation from market novelty to whether public-health agencies are prepared for products that let people trade on medical outcomes.
The tension is sharper because these markets are already live. Both Kalshi and Polymarket offer contracts related to clinical drug trials and FDA approvals, and Kalshi launched its versions in July with guardrails including late-stage trials only, completed enrollment, and employee verification technology. Kalshi’s response is that the senators’ concerns apply even more to equities markets, which gives creators a real argument to examine rather than a one-sided panic.
The broader backdrop strengthens the case. Polymarket said its annualized revenue has surpassed $1.8 billion, while the CFTC and DOJ have already brought an insider-trading case tied to Polymarket contracts involving alleged profit of about $1.2 million. CNBC also found that among 50 companies with contracts about their businesses on prediction platforms, only three disclosed policies on employee trading and 36 did not respond. That combination makes the story bigger than one letter: a growing market is meeting basic governance questions that many institutions still do not appear ready to answer.
Angles to take
Treat this as a regulatory frontier story. The key question is whether health agencies and market regulators have rules and visibility in place before trading on medical outcomes becomes normal.
Write this post →Focus on the ethics of betting on science. The senators’ case is that these contracts could undermine the scientific process, create perverse incentives for researchers, harm trial participants, and lead to dangerous medical outcomes.
Write this post →Interrogate the defense from industry. Kalshi says the same concerns apply to equities markets, and even more strongly there, which opens a useful comparison between prediction markets and existing financial markets.
Write this post →Zoom out to governance and compliance. With Polymarket citing more than $1.8 billion in annualized revenue, an alleged insider-trading case already on the books, and most contacted companies not disclosing clear employee-trading policies, the story is also about institutions lagging the market.
Write this post →